Date of event: estimated.The unique device identifier (udi) is unknown because the part and lot numbers were not provided.Implant date: estimated.The devices were not returned for evaluation as they remain implanted.The electronic lot history records (lhr) review was not performed because the part and lot numbers were not reported and the products were not returned for analysis.The reported patient effects of thrombosis and dissection are listed in the xience everolimus eluting coronary stent systems instructions for use (ifu) as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.Literature title :vascular response occurring at 3 months after everolimus-eluting cobalt¿chromium stent implantation in patients with st-segment elevation myocardial infarction vs.Stable coronary artery disease.
|
It was reported through a research article identifying xience family stents may be related to the following: incomplete neo-intimal tissue over stent struts at 3 months, intrastent thrombosis, and edge dissection.Details are listed in the article titled, "vascular response occurring at 3 months after everolimus-eluting cobalt¿chromium stent implantation in patients with st-segment elevation myocardial infarction vs.Stable coronary artery disease.".
|